Download Files:
Dovramilast
$380 – $2,850
Products Details
Product Description
– Dovramilast (CC-11050) is an orally active phosphodiesterase 4 (PDE4) inhibitor and can reduce the inflammatory response and improves Isoniazid (INH)-mediated bacillary clearance from the lungs. Dovramilast, as an adjunct, is used for the research of tuberculosis (TB)[1].
Web ID
– HY-147263
Storage Temperature
– 4°C (Powder, sealed storage, away from moisture and light)
Shipping
– Room Temperature
Applications
– COVID-19-immunoregulation
Molecular Formula
– C24H28N2O6S
References
– [1]International Nonproprietary Names for Pharmaceutical Substances (INN). WHO Drug Information, Vol. 36, No. 2, 2022.|[2]Selvakumar Subbian, et al. Pharmacologic Inhibition of Host Phosphodiesterase-4 Improves Isoniazid-Mediated Clearance of Mycobacterium tuberculosis. Front Immunol. 2016 Jun 17;7:238.
CAS Number
– 340019-69-4
Molecular Weight
– 472.55
Compound Purity
– 99.83
SMILES
– O=C(C1CC1)NC2=CC=CC(CN3[C@@H](C4=CC=C(OC)C(OCC)=C4)CS(=O)(C)=O)=C2C3=O
Clinical Information
– Phase 2
Research Area
– Infection; Inflammation/Immunology
Solubility
– DMSO : 25 mg/mL (ultrasonic;warming;heat to 60°C)
Target
– Phosphodiesterase (PDE)
Isoform
– PDE4
Pathway
– Metabolic Enzyme/Protease
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
